Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State. by Suter, M.R. et al.
Anesthesiology
 
Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the
Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State
--Manuscript Draft--
 
Manuscript Number: ALN201202011R2
Full Title: Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the
Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State
Article Type: Pain Medicine
Corresponding Author: Marc R. Suter, M.D.
University Hospital Center and University of Lausanne
Lausanne, SWITZERLAND
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University Hospital Center and University of Lausanne
Corresponding Author's Secondary
Institution:
First Author: Marc R. Suter, M.D.
First Author Secondary Information:
Order of Authors: Marc R. Suter, M.D.
Guylène Kirschmann
Cedric Laedermann, M.Sc.
Hugues Abriel, M.D., Ph.D.
Isabelle Decosterd, M.D.
Order of Authors Secondary Information:
Abstract: Background: Voltage-gated sodium channels dysregulation is an important feature of
hyperexcitability leading to pain persistence. Sodium channel blockers currently used
for the treatment of neuropathic pain are poorly tolerated or not available orally. Getting
new molecules to clinical use is an arduous process and we here propose to use a
sodium channel blocker already marketed as anticonvulsant, rufinamide.
Methods: We tested rufinamide on the Spared Nerve Injury model of neuropathic pain
in mice. We compared its effect on mechanical allodynia to amitriptyline. The effect of
rufinamide on sodium currents was tested using patch clamp in human embryonic
kidney 293 cells expressing the voltage-gated sodium channel Nav1.7 isoform and on
freshly dissociated dorsal root ganglion neurons and compared to amitriptyline and
mexiletine.
Results: In naive mice, amitriptyline (20mg/kg) increased withdrawal threshold to
mechanical stimulation from 1.3g (0.6-1.9) (median (95% confidence interval)) to 2.3g
(2.2-2.5) and latency of withdrawal to heat stimulation from 13.1s (10.4-15.5) to 30.0s
(21.8-31.9), whereas rufinamide had no effect. Rufinamide and amitriptyline alleviated
injury-induced mechanical allodynia-like behavior for 4 hours (maximal effect from
0.10±0.03g (mean±SD) to 1.99±0.26g for rufinamide and from 0.25±0.22g to 1.9±0.8g
for amitriptyline). 24 hours later, the effect had worn off. All drugs reduced peak current
and stabilized the inactivated state of voltage-gated sodium channel Nav1.7 in cell
expression system, with similar effects in dorsal root ganglion neurons.
Conclusions: At doses alleviating neuropathic pain, amitriptyline showed alteration of
behavioral response possibly related to either alteration of basal pain sensitivity or/and
sedative effect. Side effects and drug tolerance/compliance are major problems with
drugs such as amitriptyline. Rufinamide seems to have a better tolerability profile. Our
results suggest rufinamide could be a new alternative to explore for the treatment of
neuropathic pain.
Powered by Editorial Manager® and Preprint Manager® from Aries Systems Corporation
 Dear Professor Brennan,  
We are pleased to resubmit a fully revised version of our manuscript “Rufinamide attenuates 
mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes 
voltage-gated sodium channel inactivated state” for consideration for publication. 
Following your decision letter of June 7th 2012, we revised the manuscript according to the 
constructive points raised by your statistical reviewer and addressed the missing parts.  
 
Responses to the Reviewer #4:  
Global response: We changed the description of the statistical method (p. 3, l. 19), according to the 
changes mentioned in the point-to-point response below. 
 
Abstract 
1. This is simply an opinion and the authors are encouraged to revise their abstract as they see fit. 
Although describing the results of the study using a narrative style can often convey the findings of 
the study, it is far more informative to report the actually observed effects using descriptive statistics 
and measures of effect size (e.g., mean differences, odds ratios, etc.). 
 
Response: We thank the reviewer for the remark. We changed the abstract and added median with 
95% confidence interval for withdrawal threshold and withdrawal latency in naïve animals as well as 
the mean values±SD of withdrawal threshold after SNI at the peak effect for the highest drug dose. 
We also added these values in the result section under point 1.1 to 1.3. 
We did not add the values for the global effect on the stabilization effect of inactivation properties of 
Na channels (values of V1/2 inactivation, recovery from inactivation, and activity dependent block for 
each drug) because of word limitation of the abstract. 
 
Introduction 
2. When conducting inferences (i.e., significance testing using p values) it is important to formally 
state a hypothesis to test. If a p value is reported, a hypothesis is being tested. Explicitly state the 
hypothesis(es) in the Introduction section will provide a wealth of information to your readers 
concerning the expected results of the study. 
 
Response: We added the null hypothesizes tested in our experiments at the end of the introduction (p. 
6, l. 28)  
 
Methods 
3. It is important to define the measures of central tendency AND variability when they are reported 
in the methods section (e.g., mean +- SD). At present a value is reported in the methods before they 
are introduced in the stats section. Is this value a mean +- SD? 
Response: We agree with the reviewer. The only value mentioned with variability in the method 
section is the room temperature and we changed it to 21°C (p. 7, l. 44). This is how it is set in the 
animal facility but we do not have the control measurement to give a precise range of temperature at 
that period of time. We apologize for mentioning variability in the previous version. 
Response to Reviewers (RevisionsOnly)
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 4. Please ensure that exact sample sizes are available for all comparisons. Of note is that reporting a 
sample size range (e.g., "n = 4 - 10") is insufficient in this regard. 
Response: We apologize for this ambiguity which was corrected in the method section (p. 9, l. 37). 
 
Statistical Methods 
5. Several of the variables under study may violate the assumptions of parametric tests (e.g., 
normality, homogeneity of variances, level of measurement), were such assumptions considered 
prior to conducting the analysis? Several of the descriptive statistics appear to be quite skewed, 
leading to the fear that these data do not satisfy parametric assumptions. Please reconsider the 
approach. 
Response:  
We apologize if our assumptions of normality and homogeneity of variance of our variable was 
erroneous for some variables. As it is not clear which variables are questioned by reviewer 4, we go 
over all figures to hopefully clarify the analysis.  
a) We considered the measurements of mechanical allodynia using logarithmic values for 
homogeneity of variance. Threshold responses are usually normally distributed. Sometimes the 
sample for one timepoint does not pass a normality test, but this was the exception and we assumed 
the whole population does. Mainly this occurs for baseline (BL) data which are skewed because the 
upper threshold is fixed at 2.56 g (with von Frey of higher values the paw of the mice is lifted 
passively) and the distribution is only one-sided. We therefore changed our analysis for the 
development of allodynia by using a non-parametric test (Wilcoxon matched-pairs signed rank test); 
this concerns only the comparison of BL versus preinjection (post nerve injury) values. The result reject 
the null hypothesis that the values are the same (p<0.05 with Bonferrroni’s correction for multiple 
testing). The two-way repeated measures ANOVA was then used from preinjection to 24h post 
injection (precision below). 
 
b) For measures of figure 2, some variables show a skewed distribution because of fixed thresholds. 
We changed the analysis to non-parametric Kruskal-Wallis test with Dunn’s correction for multiple 
testings: 
 
For the withdrawal threshold, we obtain the following 
Kruskal-Wallis test       
P value 0.0456     
Number of groups 6     
Kruskal-Wallis statistic 11.31     
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
RUF50vF vs DMSOvF -4.438 No ns 
AMI10vF vs NaClvF10 13.69 No ns 
AMI20vF vs NaClvF20 16.88 Yes * 
 
For the withdrawal latency, we obtain the following 
Kruskal-Wallis test       
P value < 0.0001     
Number of groups 6     
Kruskal-Wallis statistic 28.31     
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Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
RUF50HP vs DMSO-HP 0.0 No ns 
AMI10HP vs NaCl-HP10 22.25 Yes ** 
AMI20HP vs NaCl-HP20 19.63 Yes * 
 
 For the total activity, we obtain the following 
Kruskal-Wallis test       
P value 0.0192     
Exact or approximate P value? Gaussian Approximation     
Kruskal-Wallis statistic 7.906     
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
NaCl vs RUF50 0.3333 No ns 
NaCl vs AMI10 7.667 Yes * 
RUF50 vs AMI10 7.333 No ns 
 
We also changed figure 2 accordingly and present the data with Box-Plot (median, box for 25th  and 
75th percentile, whiskers representing the minimum and maximum data). 
 
c) Electrophysiological measures in vitro:  
Most datasets pass the Kolmogorov-Smirnov test for normality. Some n are too small to perform 
normality tests. We assume thus that the general population of data in this section can be analyzed 
with parametrical tests. 
As asked by the reviewer we changed the results and figures to show the exact p values when 
adequate: 
- for SSI: 0.0038 for RUF, 0.0019 for AMI and 0.0003 for MEX 
-for RFI: <0.0001 for RUF (real value is 3.58E-10), 0.0011 for AMI and 0.0002 for MEX 
-for use-dependent block the tables were changed in figure 6 
 
d) Electrophysiological measures ex-vivo: 
Peak currents, activation, SSI and recovery from inactivation data are normally distributed and paired 
t-tests were used for comparison. Exact p-values are 0.0084 for peak current, 0.17 for V1/2 of 
activation, 0.35 for slope of activation, <0.0001 (0.00009) for V1/2 of steady-state inactivation, 0.34 
for slope of steady-state inactivation and 0.028 for recovery from inactivation. These values, if not 
present were added in the text. 
 
6. Please report the software that was used to conduct the statistical analyses in the statistical 
analysis section. 
Response: We apologize for the omission which was corrected (p. 14, l. 2) “Statistical analysis was 
performed using Prism 5 for windows, version 5.03, GraphPad Software, San Diego California USA” 
 
7. Please report the nature of the hypothesis testing (i.e., one-tailed versus two-tailed testing). 
Response: We apologize for the omission. This was corrected (p. 14, l. 0) “All hypotheses were 
challenged using two-tailed testing.” 
 
8. I had great difficulty following the analytical plan. As currently written, I could not replicate the 
analyses if given access to your data (which is the goal for this description). The elegant experimental 
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design naturally leads to two-way repeated measures ANOVA and this approach is introduced. 
However, there are confusing statements in the statistical methods section that indicate that a 
nonconventional approach was taken to the analysis. Statements such as "?but the statistical analysis 
was done for each group separately" indicate that a series of one-way repeated measures ANOVAs 
were conducted (and the results certainly read this way as well). This approach does not formally test 
group differences over time/dose and would not apply the proper control for multiple comparisons. 
The authors are encouraged to seek statistical consultation (if necessary) to revise either the 
description of the plan, the actual plan, and the reporting of the results (a group x time interaction 
would be extremely helpful here). 
 
Response: We apologize for the misunderstanding in the analytical plan by using the word 
“separately”. As the different rufinamide doses were not performed at the same time (to many 
groups) and in order to provide a similar environment to treated and control mice, we used a control 
group each time. We used a two-way repeated measures ANOVA for each experiment. That is: 
- RUF 25mg/kg, RUF 50mg/kg and DMSO30%, n=10, 10 and 9 respectively. Treatment comes as a 
significant source of variation with a p=0.0009, as well as time with a p<0.0001, Treatment x time 
interaction is also source of variation with a p at 0.0053. Bonferroni’s posttests comparing each 
timepoint after injection to the pre-injection value are shown on figure 1 (*p<0.05, **p<0.01, 
***p<0.001, the exact p values are not given for post-hoc testing).  
- RUF 5mg/kg, RUF 10mg/kg and DMSO30%, n=8 per group. Only time comes as a significant source 
of variation (p<0.0003). p=0.66 for treatment and 0.46 for treatment x time interaction. All pvalues 
for Bonferroni’s posttests comparing each timepoint after injection to the pre-injection value are 
above 0.05. 
- AMI 10mg/kg, AMI 20mg/kg and saline, n=10, 10 and 9 respectively. Treatment, time and treatment 
x time interaction all contribute to variation with a p<0.0001. Bonferroni’s posttests comparing each 
timepoint after injection to the pre-injection value are shown on figure 1 (*p<0.05, **p<0.01, 
***p<0.001, the exact p values are not given for post-hoc testing). 
 
In fig 1, we averaged the two DMSO control groups for the clarity of the figure. 
 
 
9. Related to the above, the practice of applying a series of unprotected paired t-tests in Figure 2 
violates the Journal's family-wise error rate policy. Please revise this approach to account for the fact 
that multiple comparisons are being made.  
Response: We thank the reviewer for this precision. The approach has been revised (see above, point 
5). 
 
Results 
10. Although the reporting of p values using "p <" or "p >" is still acceptable to many journals, 
reporting the exact p values (e.g., p = 0.031) is preferred. This reporting practice even applies to p 
values that are statistically non-significant (e.g., p = 0.54) 
Response: We changed wherever necessary with exact p values, except for posttests when only the 
approximation is available in GraphPad (*p<0.05, **p<0.01, ***p<0.001). We also left “p<” when 
more than 4 digits were necessary.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11. Unless explicitly stated, it can often be difficult to tell if any of the measurements were lost to 
observation or were missing in the analysis. Were any data missing for any of the variables? The 
methods state that certain cells were not used in the analysis. Some estimates of the lost data must 
be provided to your reader.  
Response: No data were missing for behavior after drug delivery. For electrophysiology, once the cells 
were sealed, around 15% of cells were lost before any measurement with drug could be completed. 
This was added in the method (p. 10, l. 48) 
 
General 
12. The reporting of standard error of the mean (SEM or SE) as a measure of variability is certainly 
commonplace and is routinely encountered. However, as a measure of variability, perhaps there are 
better choices than SEM. When simply describing the sample, standard deviation (SD) provides a 
measure of variability that is less abstract and can be directly used for standard effect size 
calculations. When appealing to the sampling distribution, +-SEM is actually a 68% confidence 
interval that is of little use for conventional inference testing. A much more informative choice would 
be to report a 95% confidence interval in the text, tables, and figures.  
Response: We changed figure 1 to show SD instead of SEM as suggested by the reviewer. On figure 2 
as mentioned above we changed the graphical representation to box-plot. SD was already used for 
the other figures. 
 
13. The use of the term "significant" has been found without an important modifier in numerous 
places in the manuscript. While discussing a "significant effect" is relatively common, it is not nearly 
as informative (or precise) as discussing a "statistically significant effect" or a "clinically significant 
effect". Please reconsider the use of 'significant" throughout the manuscript. 
Response: We thank the reviewer for the comment and verified the use of “significant” throughout 
the manuscript. 
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Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in 
the mouse and stabilizes voltage-gated sodium channel inactivated state 
Marc R. Suter1,2, MD, Anesthesiology Fellow, Guylène Kirschmann1, Laboratory 
technician, Cedric Laedermann1,3, MSc, PhD student, Hugues Abriel3, MD, PhD, Professor, 
Isabelle Decosterd1,2,4, MD,  Associate Professor 
 
1Pain Center, Department of Anesthesiology, University Hospital Center and University of 
Lausanne, 1011 Lausanne, Switzerland (work attributed to) 
2for the Swiss Pain Research Consortium, Zurich, Switzerland,  
3Department of Clinical Research, University of Bern, Bern, Switzerland 
4Department of Cell Biology and Morphology, University of Lausanne, 1011 Lausanne, 
Switzerland 
Corresponding author: 
Marc R. Suter 
Pain Center, Department of Anesthesiology 
CHUV 
Avenue du Bugnon 46 
1011 Lausanne 
Switzerland 
Phone: +41 79 5563479, fax : +41 21 314 2004 
Email: marc.suter@chuv.ch 
 
This study was supported by the Swiss National Science Foundation (Swiss Pain Research 
Consortium, Special Program University Medicine grant, 33CM30-124117 to I.D. and M.S. 
and grant 310030B_135693 to H.A.), Bern, Switzerland, the Swiss Society of 
Anesthesiology, Bern, Switzerland and the University of Bern, Bern, Switzerland.  
 
Work presented at: 
International Association for the Study of Pain meeting, Montreal, Quebec, Canada, 
September 2010  
Effect of rufinamide on gating properties of voltage-gated sodium channel Nav1.7, MR 
Suter, H Abriel, I Decosterd 
European Society of Anaesthesiology meeting, Amsterdam, Netherland, June 2011 
Rufinamide alleviates mechanical allodynia in a mouse neuropathic pain model 
*Manuscript (Title Page, Abstract, Body, References)
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MR Suter, G Kirschmann, H Abriel, I Decosterd 
Number of words in Abstract (285), in Introduction (543), and in Discussion (1661) 
Running title: 
Rufinamide reduces neuropathic pain in the mouse 
 
Brief summary: 
The anti-epileptic drug rufinamide alleviates mechanical allodynia in a neuropathic pain 
model with less side-effect than amitriptyline, one of the first line treatments for 
neuropathic pain. Rufinamide stabilizes sodium channels in their inactivated state. 
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Abstract: 
Background: Voltage-gated sodium channels dysregulation is an important feature of 
hyperexcitability leading to pain persistence. Sodium channel blockers currently used for 
the treatment of neuropathic pain are poorly tolerated or not available orally. Getting 
new molecules to clinical use is an arduous process and we here propose to use a sodium 
channel blocker already marketed as anticonvulsant, rufinamide.  
Methods: We tested rufinamide on the Spared Nerve Injury model of neuropathic pain in 
mice. We compared its effect on mechanical allodynia to amitriptyline. The effect of 
rufinamide on sodium currents was tested using patch clamp in human embryonic kidney 
293 cells expressing the voltage-gated sodium channel Nav1.7 isoform and on freshly 
dissociated dorsal root ganglion neurons and compared to amitriptyline and mexiletine.  
Results: In naive mice, amitriptyline (20mg/kg) increased withdrawal threshold to 
mechanical stimulation from 1.3g (0.6-1.9) (median (95% confidence interval)) to 2.3g 
(2.2-2.5) and latency of withdrawal to heat stimulation from 13.1s (10.4-15.5) to 30.0s 
(21.8-31.9), whereas rufinamide had no effect. Rufinamide and amitriptyline alleviated 
injury-induced mechanical allodynia-like behavior for 4 hours (maximal effect from 
0.10±0.03g (mean±SD) to 1.99±0.26g for rufinamide and from 0.25±0.22g to 1.9±0.8g 
for amitriptyline). 24 hours later, the effect had worn off. All drugs reduced peak current 
and stabilized the inactivated state of voltage-gated sodium channel Nav1.7 in cell 
expression system, with similar effects in dorsal root ganglion neurons. 
Conclusions: At doses alleviating neuropathic pain, amitriptyline showed alteration of 
behavioral response possibly related to either alteration of basal pain sensitivity or/and 
sedative effect. Side effects and drug tolerance/compliance are major problems with 
drugs such as amitriptyline. Rufinamide seems to have a better tolerability profile. Our 
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results suggest rufinamide could be a new alternative to explore for the treatment of 
neuropathic pain. 
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Introduction: 
Pain is essential for survival as it serves as an alert to engage protective behavior. 
Neuropathic pain defined by the International Association for the Study of Pain as “pain 
caused by a lesion or disease of the somatosensory nervous system” affects 7% of the 
population1 and possesses no protective purpose. 
Sodium channels are major targets for the development of new drug to treat neuropathic 
pain2. Nerve  injury changes the expression (number, subtypes) of sodium channels3 
which affects peripheral nerve hyperexcitability and ectopic discharges along the nerve, 
in the dorsal root ganglion or at the injury site where a neuroma forms4;5. They are 
composed of a -pore forming subunit associated to one or two -modulating subunits. 
Nine genes encodes for the -subunits, Nav1.1-1.96. 
Current therapy for neuropathic pain involves adjuvant medications - not primarily 
developed for this purpose - such as anticonvulsants, antidepressants or local 
anesthetics7. Tricyclic antidepressants are the most studied family of antidepressant in 
pain therapy and considered as first line treatment in different international guidelines8. 
Their mode of action does not seem to be linked to their antidepressant actions as 
acknowledged by their faster onset9. Among other members of that family, amitriptyline 
was shown to interact with sodium channels as exemplified by its cardiac toxicity and this 
target could also play a role in pain modulation10. Mexiletine, a sodium channel blocker 
and an oral analog of local anesthetics has been used in the treatment of neuropathic 
pain11 but its tolerance on long term therapy raises considerable questions as shown by a 
median discontinuation of treatment of 43 days in a recent study12. Rufinamide is an 
antiepileptic drug licensed for a refractory type of epilepsy in the childhood, the Lennox-
Gastaut syndrome13. Its principal mechanism of action is considered to be inhibition of 
sodium channels, stabilizing its inactive form and reducing the firing of sodium 
dependent action potentials14.  
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Since the discovery that loss-of-function mutations in SCN9A, the gene encoding for 
Nav1.7 isoform, are associated with congenital insensitivity to pain15, it has become a 
potential target for treatment. Moreover, gain-of-function mutations SCN9A are 
associated with familial pain syndromes (erythromelalgia and paroxysmal extreme pain 
disorder reviewed by Lampert16) and in subset of patients with idiopathic small nerve 
fiber neuropathy or generalized pain syndromes17;18. Nav1.7 is expressed in sensory, 
sympathetic and myenteric fibers19-21. It exhibits slower recovery from fast 
inactivation22;23 compared to other tetrodotoxin-sensitive channels Nav1.4 and 1.6 and 
slower inactivation at potentials close to the membrane resting potential, thus 
contributing to the large ramp current during slow depolarization24. Nav1.7 is thought to 
play an important role in “boosting” the depolarization of small diameter nociceptive 
neurons. 
 
In the present study, we investigated the analgesic effect of rufinamide on the spared 
nerve injury (SNI) model of neuropathic pain and amitriptyline was used as a positive 
control. Our null hypothesis was that treated and control groups show the same 
behavior. We also explored the effect of rufinamide on Nav1.7 channels heterogeneously 
expressed in human embryonic kidney 293 cells and used mexiletine and amitriptyline as 
control. We finally tested the effect of rufinamide on dorsal root ganglia neurons. In 
these electrophysiological experiments our null hypothesis was that the drugs do not 
change the measured parameters, which were V1/2 of activation and steady-state 
inactivation and t1/2 of recovery from inactivation. 
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Materials & Methods: 
Drugs: 
Rufinamide (R8404), amitriptyline (A8404) and mexiletine (M2727) were purchased from 
Sigma (Buchs, Switzerland). For behavioral experiment, rufinamide was dissolved in 
dimethylsulfoxide (DMSO) and then mixed with 1x phosphate buffered saline to the 
desired concentration. Control was 30% DMSO in 1x phosphate buffered saline. Doses 
(5, 10, 25, 50 mg/kg) were chosen corresponding to the therapeutic ones used in 
epilepsy models in mice (rufinamide was effective in the maximal electroshock test (ED 
23.9 mg/kg orally) and in the pentylenetetrazol induced seizure test (54 mg/kg, 
intraperitoneally)25. Amitriptyline was dissolved directly in sterile 0.9% saline and doses 
were chosen according to previous studies in neuropathic pain models. Drugs were 
administered intraperitoneally. 
 
Animal experiments: 
All experiments were approved by the Committee on Animal Experimentation of the 
Canton de Vaud, Lausanne, Switzerland, in accordance with Swiss Federal law on animal 
care and the guidelines of the International Association for the Study of Pain26. Five-
week-old C57BL/6 male mice (Charles River, l’Abresle, France) weighting 20-25g at the 
start of experiment were housed in the same room, 5 per cage, at constant temperature 
of 21°C and a 12/12 dark/light cycle. No other animals were housed in that room. Mice 
had ad libitum access to water and food.  
Surgery 
SNI surgery27;28 on mice29 was performed under 1.5–2.5% isoflurane (Abott AG, Baar, 
ZG, Switzerland) anesthesia. Briefly, the left hindlimb was immobilized in a lateral 
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position and slightly elevated. Incision was made at mid-thigh level using the femur as a 
landmark and a section was made through the biceps femoris in the direction of point of 
origin of the vascular structure. The three peripheral branches (sural, common peroneal 
and tibial nerves) of the sciatic nerve were exposed without stretching nerve structures. 
Both tibial and common peroneal nerves were ligated using a 6.0 silk suture and 
transected together. The sural nerve was carefully preserved by avoiding any nerve 
stretch or nerve contact. 
Behavior 
For all the behavioral experiments, the observer was blinded to the treatment applied. 
Mechanical sensitivity: Animals were habituated to the testing environment daily for at 
least 2 days before baseline testing. The room temperature and humidity remained 
stable for all experiments. For testing mechanical sensitivity, animals were put under 
inverted plastic boxes on an elevated mesh floor and allowed 10 min for habituation 
before the threshold testing. Mechanical allodynia was tested using a series of von Frey 
hairs with logarithmically incrementing stiffness (0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 
1.28, and 2.56 g). The filaments were applied perpendicularly to the plantar surface 1–2 
s. The 50% withdrawal threshold was determined using Dixon’s up–down method30. 
Heat sensitivity: The effect of rufinamide and amitriptyline on basal heat sensitivity was 
assessed with the Hot Plate assay. Briefly, the animals were placed on the hot-plate 
surface set at 52°C. The latency of response (in seconds) was determined as the time 
until a hindlimb lick or jump occurred. The cutoff was set at 30 s to avoid tissue damage. 
Activity was quantified with the Activ-meter (Bioseb, France). The total activity 
(summation of immobile, slow and fast activity given by the software) of naive animals in 
their home cage was measured during the 4 hours following injection of rufinamide (50 
mg/kg) and amitriptyline (10 mg/kg). It was compared to the activity after saline 
injection. All experiments for activity were performed between 5 and 9pm. 
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A 5 point sedation score from 0-4 points was used for rufinamide (50 mg/kg) and 
amitriptyline (10 mg/kg), 0=normal behavior, normal locomotion, 1=awake, slow 
locomotion, 2=no locomotion, eyes half closed, still responding to righting reflex, 
3=asleep, eyes closed, still responding to righting reflex, 4=no righting reflex, adapted 
from Boast et al.31.  
 
Experimental design 
For drug effect on naïve animals, 8 animals per group were used to assess mechanical 
withdrawal threshold and heat withdrawal latency. For the Activ-meter, 6 animals were 
used in a cross-over design for rufinamide and amitriptyline. 
Normal mechanical threshold was assessed before surgery without difference between 
groups. SNI surgery was performed and one week later allodynia-like behavior was 
tested before intraperitoneal injection of rufinamide. Two series of experiments were 
done, the first one compared rufinamide 25 mg/kg and 50 mg/kg to DMSO 30% (n=10 
per group, 9 for DMSO) and the second one compared rufinamide 5 mg/kg and 10 mg/kg 
to DMSO 30% (n=8 per group) at 20-40-60-120-240 min and 24 h. After a washout 
period of one week the animals of the first series were tested with amitriptyline 10 or 20 
mg/kg or saline at 60-120-240 min and 24 h after intraperitoneal injection (n=9 per 
group for amitriptyline 20mg/kg and 10 per group for amitriptyline 10mg/kg and saline).  
Plasma levels of the drug were assessed at 120 min after injection of 50 mg/kg 
rufinamide. Mice (n=3) were anesthetized with isoflurane and 1 ml of blood was collected 
intracardially. Drug levels were analyzed by the pharmaceutical monitoring laboratory of 
Lavigny, Switzerland (http://www.ilavigny.ch/html/hopital/laboratoire.php, last accessed 
June 21st 2012). 
 
Electrophysiology: 
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Rufinamide was dissolved in DMSO at 10mol/l as stock solution and diluted daily at 
desired concentration in the extracellular medium. As control the same DMSO 
concentration was used (1% for 100 g/ml, to 5% for 500 g/ml). Higher concentration 
could not be achieved without increasing DMSO content. Amitriptyline and mexiletine 
were dissolved in extracellular medium directly. 
Human embryonic kidney 293 cells stably expressing Nav1.7 were kindly provided by 
Simon Tate (PhD, Chief Scientific Officer, Convergence Pharmaceuticals, Cambridge, UK) 
and were cultured in DMEM-F12 + L-Glutamine (Invitrogen, Merelbeke, Belgium) 
supplemented with 5% fetal bovine serum and geneticin 0.4 mg/ml. Measurements were 
made at room temperature using pClamp software, version 10.2, and a VE-2 amplifier 
(Alembic Instruments, Montreal, Quebec, Canada). The sampling rate was 30 kHz. Data 
were smoothed and analyzed using Clampfit software version 10.2.0.12 (Axon 
Instruments, Union City, CA), and KaleidaGraph (Synergy Software, Reading, PA).  
Whole-cell Patch clamp recordings were conducted using an internal solution containing 
(in mmol/l) CsCl 60, Cesium aspartate 70, EGTA 11, MgCl2 1, CaCl2 1, HEPES 10, and 
Na2-ATP 5, pH adjusted to 7.2 with CsOH; and an external solution containing NaCl 50, 
n-methyl-D-glutamine-Cl 80, CaCl2 2, MgCl2 1.2, CsCl 5, HEPES 10, and glucose 5, pH 
adjusted to 7.4 with CsOH. Holding potential was -100 mV. The values were not 
corrected for liquid junction potential. Pipette resistance was ranging from 2 to 4 MOhm. 
Only data from cells having stable access resistance over the duration of the experiment 
were used. Cells for which signs of poor voltage-clamp control, such as delayed 
inflections of the current or discontinuities in the peak INa versus Vm curve were not 
analyzed. Around 15% of sealed cells were lost.  Data were filtered after acquisition 
using Boxcar 9 points. Peak currents were measured with a single 10ms pulse protocol to 
-10mV from the holding potential. Percentage inhibition was calculated as (peakvehicle- 
peakdrug)/peakvehicle x100 for each cell and then mean inhibition for each drug and 
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concentration was calculated. Other protocols are shown as inserts in the figures. The 
linear ascending segment of the current-voltage relationship was used to estimate the 
reversal potential for each trace before obtaining the voltage–dependent activation 
curve. Voltage dependence of activation and steady state inactivation curves were 
individually fitted with Boltzmann relationships, y(Vm) = 1/(1 + exp[(Vm - V1/2)/K]) in 
which y is the normalized current or conductance, Vm is the membrane potential, V1/2 is 
the voltage at which half of the channels are activated or inactivated and K is the slope 
factor. The value of t1/2 of recovery from inactivation was calculated by interpolation from 
a linear relation between the 2 points juxtaposing half recovery (y1<0.5<y2), using the 
relation x = [0.5-(y1x2-y2x1)/(x2-x1)]*(x2-x1)/ (y2-y1). For use-dependent block, the 
percentage of decrease of current was calculated between the 1st and 50th pulse. 
For ex-vivo recordings, dorsal root ganglion neurons were collected from adult C57BL/6 
mice (4-8 weeks old). Briefly, L4 and L5 dorsal root ganglion neurons were harvested 
and digested in Liberase blendzyme TM (Roche, Indianapolis, USA) 0.5U/dorsal root 
ganglion with 12 M EDTA in 5 ml Complete Saline Solution (in mmol/l, NaCl 137, KCl 
5.3, MgCl2-6H2O 1, Sorbitol 25, HEPES 10, CaCl2 3 and pH adjusted to 7.2 with NaOH) 
for 20 min at 37°C. Neurons were further digested with Liberase blendzyme TL with 
EDTA in Complete Saline Solution with papaïn (30U/ml) for 10 min. Finally neurons were 
suspended in dorsal root ganglion medium mix (89% DMEM/F-12, 10% BSA, 1% 
penicillin/streptomycin) supplemented with 1.5 mg/ml of trypsin inhibitor and 1.5 mg/ml 
of purified BSA. Mechanical dissociation was performed using a pipetman and neurons 
were plated on poly-D-lysine coated coverslips and incubated 12 hours before recording 
to allow recovery and adhesion of neurons. Neurons were only recorded for 12 more 
hours to prevent long-term culture phenotypic changes and neurite outgrowth that 
degrades space clamp. Small neurons (diameter <30m) were recorded using an EPC-10 
amplifier (HEKA Electronics, Lambrecht, Germany) and Patchmaster/Fitmaster software 
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for data acquisition/analysis. The sampling interval was 20 μs and a 5 kHz filter was used 
in all experiments. Experiments were carried out in the whole-cell patch clamp 
configuration. Extracellular solution contained (in mmol/l) NaCl 30, TEA–Cl 110, KCl 3, 
CaCl2 1, MgCl2 1, HEPES 10, Glucose 10, CdCl 0.1; pH was adjusted to 7.3 using Tris 
base, osmolarity was adjusted to 320 mosm/l with sucrose. The pipette solution 
contained CsF 140, NaCl 10, MgCl2 2, CaCl2 0.1, EGTA 1.1, HEPES 10, pH was adjusted 
to 7.2 with CsOH and osmolarity was adjusted to 310 mosm/l. Pipettes were pulled from 
Borosilicate glass (World Precision Instruments, Sarasota, FL, USA) and had a resistance 
< 3 MΩ, when filled with the pipette solution. Capacity transients were cancelled and 
series resistance was compensated to around 90%. Leakage current was digitally 
subtracted online using hyperpolarizing control pulses, applied after the test pulse, of 
one-fourth test pulse amplitude (P/4 procedure). For current density measurements, 
membrane currents were normalized to the membrane capacitance which was calculated 
from the integral of the transient current in response to a brief hyperpolarizing pulse of 
10 mV from the holding potential.  
Once in whole cell configuration, cells were held at -60 mV for 5 minutes to dialyze the 
cell with CsF solution (fluoride shifts Nav1.8 steady-state activation and inactivation to 
hyperpolarized potentials) to reach Nav1.8 stable biophysical properties and to inactivate 
Nav1.9 current and was further clamped at -80 mV for 2 more minutes. Whole-cell Na 
currents were elicited by a series of 100 ms test pulses ranging from -80 mV to +40 mV 
in increments of 5 mV at a frequency of 0.33 Hz. Test pulses were preceded by a 
prepulse of 3 s at -120 mV. Normalized conductance (G/Gmax) was fitted as described 
for in vitro recordings and V1/2 and slope factor were extracted from the equation. Steady 
state inactivation curves (SSI) were measured from a holding potential of −120 mV using 
500 ms prepulses to the indicated potentials followed by a test pulse to 0 mV. Again, V1/2 
and slope factors were obtained as mentioned for in vitro recordings. 
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Recovery from inactivation curves were obtained with a standard two-pulse protocol 
consisting of a depolarizing pulse from a holding potential of -120 mV, to 0 mV for 50 ms 
to inactivate the channels, followed by a variable duration step (from 0.05 ms to 3276.8 
ms) back to -120 mV to promote recovery. The availability of the channels was assessed 
with a second test pulse at 0 mV and the ratio of the second pulse versus the first was 
plotted against the recovery interval. The t1/2 of recovery was calculated as mentioned 
previously. 
Statistics:  
-Behavioral statistics: For the time course and drug effect on mechanical allodynia after 
nerve injury 3 experiments were done separately: i) rufinamide 25mg/kg, rufinamide 
50mg/kg and DMSO30%, ii) rufinamide 5mg/kg, rufinamide 10mg/kg and DMSO30%, iii) 
amitriptyline 10mg/kg, amitriptyline 20mg/kg and saline. The log values of withdrawal 
thresholds were assessed for each experiment using an Anova two-ways with Bonferroni 
correction for repeated measures from preinjection to 24h after injection. For the 
development of allodynia, baseline and preinjection were compared by using the 
Wilcoxon matched-pairs signed rank test (Bonferroni’s correction for multiple testing) 
because baseline values are skewed. For clarity purposes on figure 1, a mean value of 
both DMSO groups is used and values are presented as mean±SD also for baseline. For 
the drug effect on naïve animals, data were analyzed with Kruskal-Wallis test and Dunn’s 
correction for multiple testing. The numerical data are presented as median with 95% 
confidence interval.  
-Electrophysiological statistics: Data are presented as mean±SD and were analyzed using 
paired student’s t tests for drug effect.  
All hypotheses were challenged using two-tailed testing and p<0.05 was used as the 
level of significance. Statistical analysis was performed using Prism 5 for windows, 
version 5.03, GraphPad Software, San Diego California USA.
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Results: 
1. Behavior 
1.1 Rufinamide reduces mechanical allodynia following SNI 
All animals developed allodynia one week after surgery (p<0.05, preinjection versus 
baseline for all groups). Rufinamide significantly and dose dependently alleviated SNI-
induced allodynia (Fig. 1A), with maximal effect from 0.10±0.03g (mean±SD) to 
1.99±0.26g. The effect was seen already 20 minutes following injection, peaked at 60 
min, lasted for at least 4 hours, but had faded 24 hours after drug administration. At the 
highest dose of rufinamide, allodynia-like behavior was completely reversed. The vehicle 
DMSO showed a tendency for anti-allodynic effect but the values did not reach statistical 
significance in multiple testing. 
 
1.2 Amitriptyline reduces mechanical allodynia following SNI 
All animals showed allodynia before injection of amitriptyline (p<0.05 preinjection versus 
baseline for all groups). Amitriptyline alleviated the allodynic behavior from 60 to 240 
min after injection and the effect had disappeared at 24h (Fig. 1B) with maximal effect 
from 0.25±0.22g to 1.9±0.8g. There was no difference between 10 and 20 mg/kg. 
 
1.3 Amitriptyline but not rufinamide affects basal sensitivity 
Rufinamide (50mg/kg) did not modify basal mechanical sensitivity of naive animals or 
heat withdrawal latency. We therefore did not test lower doses (Fig. 2A-B). On the other 
hand, amitriptyline at 20 mg/kg increased withdrawal threshold for innocuous mechanical 
stimulation with von Frey hair from 1.3g (0.6-1.9) (median and 95% confidence interval) 
to 2.3g (2.2-2.5) and increased withdrawal latency on heat stimulation compared to 
saline from 13.1s (10.4-15.5) (median, 95%CI) to 30.0s (21.8-31.9). We therefore 
tested amitriptyline at 10 mg/kg and also observed antinociceptive effect on heat 
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stimulation (withdrawal threshold from 10.5s (7.2-11.7) to 25.3s (16.4-27.7)), but no 
statistically significant difference on non-noxious mechanical stimulation (Fig. 2A-B).  
Animals injected with rufinamide 50 mg/kg did not lower their total activity measured 
over 4 hours after injection with the Activ-meter as compared to saline injected controls. 
Amitriptyline decreased total activity statistically significantly compared to saline injected 
controls (Fig. 2C). 
Amitriptyline increased the score of sedation from 0 (saline group) to 2[0-3] (median, 
[range], n=8). Rufinamide did not change the score (0). 
 
1.4 Rufinamide plasma level corresponds to therapeutic level for epileptic patients  
At peak effect for mechanical allodynia, the range of plasma level for rufinamide was 68-
86 mol/l.  
 
2. Effect of rufinamide on Nav1.7 channel compared to amitriptyline and mexiletine 
2.1 Rufinamide reduces Nav1.7 peak current  
Rufinamide reduced peak sodium current (INa) induced by a single pulse depolarization 
using human embryonic kidney 293 cells stably expressing Nav1.7 (Fig. 3). The most 
substantial reduction obtained with rufinamide was 28.3%, at a concentration of 500 
mol/l. The drug could not be dissolved at higher concentration. A concentration of 100 
mol/l was used for the rest of the testing to avoid the high DMSO concentration used for 
500mol/l. With high concentration of amitriptyline and mexiletine a complete inhibition 
of INa could be obtained and EC50 were used for the following experiments (Fig. 3).  
 
2.2 Rufinamide shifts steady-state inactivation of Nav1.7 
The voltage dependence of activation was examined using a series of 10 ms depolarizing 
test pulses from -80 to +85 mV from a holding potential of -100 mV. Rufinamide had no 
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effect on voltage-dependency of activation for Nav1.7 sodium channel, nor did 
amitriptyline and mexiletine. No statistically significant changes were seen in V1/2 of 
activation. Slopes were slightly altered by rufinamide and mexiletine (Fig. 4). For the 
steady-state inactivation experiments, cells were given a 500 ms conditioning pulse at 
voltages between −130 mV and −10 mV from a holding potential of -100 mV followed by 
a 20 ms test pulse. Normalized sodium currents (INa/Imax) measured during test pulses 
were plotted against conditioning voltage. Rufinamide shifted the steady-state 
inactivation relationship to more hyperpolarized value with a V1/2 of inactivation shifting 
from -81.0±4.4 to -87.6±4.9 mV. The control drugs had a similar effect with shift of V1/2 
of inactivation, from -81.8±2.8 to -88.4±1.1 mV for amitriptyline and from -80.0±3.0 to 
-91.4±2.6 mV for mexiletine. The slopes of steady-state inactivation curves were not 
influenced by any of the tested drugs (Fig. 4). 
 
2.3 Rufinamide prolongs the recovery from fast inactivation of Nav1.7 
Effects on the recovery from fast inactivation was examined with a standard double-pulse 
protocol consisting of a depolarizing pulse to -10 mV to inactivate the channels followed 
by a variable duration (0.25 to 2000 ms) step to the holding potential of -100 mV to 
promote recovery. The availability of the channels at the end of the recovery interval was 
assessed with a standard test pulse. The ratios of response of 2nd/1st pulse were plotted 
versus the recovery interval. The t1/2 of recovery was interpolated. It was statistically 
significantly prolonged for the 3 tested drugs (Fig. 5).  
 
2.4 Rufinamide shows use-dependent inhibition of Nav1.7 
Frequency-dependent or use-dependent blocking refers to the accumulation of channels 
in inactivated state when subjected to a train of depolarizing pulses at high frequency. 
We applied a series of 50 pulses at varying frequencies (2, 5, 10, 25, 50Hz) and plotted 
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the normalized current against the pulse number. Rufinamide at 100 mol/l increased the 
use-dependent block at all frequencies tested, except 2Hz. Amitriptyline and mexiletine 
also increased the use-dependent block, even at 2 Hz (Fig. 6).  
 
3. Rufinamide influences INa in dorsal root ganglion neurons  
We then wanted to validate the effect of rufinamide using dissociated mouse dorsal root 
ganglion neurons which contain also other Nav channels and the -subunits. We first 
observed that rufinamide at 100 mol/l consistently induced a statistically significant 
10.1% mean reduction in peak sodium current densities from 956±396 to 850±339 
pA/pF (p<0.05) despite a great variability in absolute values of current density (Fig. 7A). 
We then assessed voltage-dependence of activation and inactivation of the sodium 
current on the dorsal root ganglion with step protocols. The global effect of rufinamide on 
dorsal root ganglion was similar to the one observed using human embryonic kidney 293 
cells expressing only Nav1.7. The voltage-dependence of activation was unchanged and 
the inactivation curve was shifted with statistical significance toward more hyperpolarized 
potentials, from a V1/2 of inactivation of -64.4±16.8 mV to-69.4±17.1 mV (p<0.0001) 
(Fig. 7B). Finally we observed that rufinamide also delayed t1/2 of recovery from 
inactivation from 2.58±2.12 to 6.24±5.04 ms (p<0.05) (Fig. 7C). 
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Discussion:  
We here demonstrate that rufinamide alleviates mechanical allodynia-like behavior in the 
SNI model of neuropathic pain in mice. Its effect is comparable to amitriptyline, but with 
no interference on basal sensitivity and activity tests. We also show that rufinamide 
modulates Nav1.7. It stabilizes the channel in its inactivated state similarly to 
amitriptyline and mexiletine, and delays its recovery from inactivation. By the 
observation of rufinamide effect on total sodium currents recorded in dorsal root ganglion 
neurons, we finally validated a potential peripheral mechanism of action of rufinamide for 
the treatment of neuropathic pain. 
 
Effect of rufinamide on mechanical allodynia following SNI in mice 
We present a robust effect of amitriptyline and rufinamide on SNI-induced mechanical-
allodynia in mice. To our knowledge, this is the first trial testing rufinamide in a model of 
neuropathic pain.  
Amitriptyline is a first line treatment for clinical neuropathic pain8. Amitriptyline alleviates 
neuropathic pain-like behavior in the chronic constriction injury32;33 and spinal nerve 
ligation models34. In other studies it failed to affect mechanical allodynia in these 
models35;36 or on paw pressure hypersensitivity in a rat diabetes-related pain model37. In 
the SNI model, in rats, amitriptyline decreased mechanical allodynia in the early 3-5 days 
post injury38 whereas it failed to show an effect 2 to 4 weeks after nerve injury39. When 
administered perisurgically for 1 week, amitriptyline failed to prevent the development of 
mechanical allodynia in rodents40.  
Despite diverging results explained by the different sensory modalities tested, timing, 
dose and administration route or species/genetic background41;42, the SNI model remains 
a robust neuropathic pain model in rodents. In rats, mechanical allodynia following SNI 
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does not respond to moderate doses of morphine, gabapentin, carbamazepine, MK-80139, 
lidocaine, lamotrigine43 or rofecoxib44. Other groups  showed a  transient effect of high 
dose of morphine (6 mg/kg, effect < 3hours), mexiletine (37 mg/kg, < 1 hour) or 
gabapentin (100 mg/kg, < 5 hours)45 and tocainide43. Side effects and sedation are 
rarely mentioned but with high doses, many of the tested drugs in SNI could impair basal 
sensitivity39.  
Rufinamide alleviates dose-dependently mechanical allodynia in this model, without 
inducing any changes in sedation or affecting basal sensitivity. Amitriptyline reduced 
allodynia, but also modified basal pain sensitivity and sedation score, which could 
participate in its anti-allodynic effect. Amitriptyline has been shown previously to change 
locomotor activity in rodents due to sedation, ataxia, changes in nociception, depression 
or anxiety46-50. In one study amitriptyline did not change locomotor activity in the chronic 
constriction injury model despite reducing allodynia. We are in agreement with others 
who showed an increase in thermal latency after acute amitriptyline treatment46;51. 
Rufinamide has the potential of a new treatment for neuropathic pain 
As first line therapy for the treatment of neuropathic pain, clinical guidelines propose 
tricyclic antidepressants (amitriptyline), serotonin and norepinephrine reuptake inhibitors 
(duloxetine and venlafaxine) or anticonvulsants targeting α2-δ subunit of calcium 
channels (gabapentin and pregabalin)8;52. The most effective antidepressants in the 
treatment of neuropathic pain have sodium channel blocking properties53, which may 
contribute to their analgesic activity10;54. The use of sodium channel blockers as a first-
line evidence-based treatment recommendation has not yet been suggested except for 
two specific conditions: carbamazepine in trigeminal neuralgia52 and topical lidocaine in 
postherpetic neuralgia with irritable nociceptor11. The systemic delivery of a sodium 
channel blocker is limited by the poor tolerability (and restricted availability in many 
countries) of mexiletine as well as the high risk of drug interaction with carbamazepine55.  
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Rufinamide offers a valuable alternative to tricyclic antidepressants / serotonin and 
norepinephrine reuptake inhibitors and calcium channel α2-δ ligand for the 
pharmacologic management of neuropathic pain. 
In clinical practice, the efficacy of amitriptyline on neuropathic pain is variable56;57. 
Amitriptyline is well known for its side effects, predominantly sedation, hypotension and 
anti-cholinergic effects, considerably reducing patient’s compliance58. In particular, 
sedation has been known for a long time even at “light” dosage (50 mg)59;60. For 
rufinamide, in a study for Lennox-Gastaut syndrome, the incidence of adverse events for 
somnolence or vomiting was more common in the rufinamide treated group13, but 
causing only 2 respectively 3 patients out of 74 to withdraw from the study. 
Drug interaction is also a major issue for pain therapy. Rufinamide presents favorable 
pharmacokinetic parameters; it is well absorbed orally and is not a substrate of 
cytochrome p450 system, thereby reducing its potential interactions. It is however a mild 
inducer of CYP3A461. Rufinamide may be a mood-stabilizing molecule with anxiolytic 
properties62 that could be an added value considering the large proportion of psychiatric 
mood-disorders encountered in chronic pain patients63. The toxicity studies in rodents 
show a greater safety ratio than other anticonvulsants25. Na channels are still a major 
target in the development of new analgesic drugs23;64, but rufinamide already being on 
the market, might offer a new treatment opportunity in the pain field, while other drugs 
trying their way through clinical trials have failed65;66.  
 
Site of action of Rufinamide 
Rufinamide is a sodium channel blocker but its exact mechanism and site of action are 
unknown. Its effects on biophysical properties of sodium currents are similar to 
amitriptyline and mexiletine. Amitriptyline apparently interacts with residues on the 
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DIVS6 segment67 but also DIS6, DIIIS6 and DIVS6 segments, which may jointly form 
parts of the amitriptyline/local anesthetic receptor68. 
The importance of DIVS6 segment in mexiletine binding to sodium channel has also been 
demonstrated69. Further studies are needed to investigate the site of action of rufinamide 
on Nav1.7 and other channel isoforms, but a similar site can be hypothesized from the 
properties of stabilization of the inactivated state shown here. Following the recent report 
of the crystal structure of the voltage-gated sodium channel we hope new mechanistic 
knowledge will be gained in drug-channel interactions70. 
 We demonstrated the action of rufinamide on the peripherally expressed Nav1.7 isoform 
of sodium channel but we do not intend to show any specific Nav1.7 blocking properties. 
Indeed the drug is used in the treatment of epilepsy and therefore should also act on 
centrally expressed sodium channels.  Rufinamide showed no relevant interaction with 
monoaminergic binding sites in radioligand binding studies and no interactions with 
benzodiazepine or gamma-aminobutyric acid (GABA) receptors, 5-HT1 and 5HT2 
receptors, α- or β-adrenoceptors, or human recombinant metabotropic glutamate 
receptor subtypes 1b, 2, or 4 (mGluR1b, mGluR2, mGluR4). However, an inhibitory effect 
of rufinamide at the mGluR5 subtype was observed at 100 mol/l61. mGluR5 is 
upregulated in the dorsal root ganglia and spinal cord after spinal nerve ligation (but not 
after partial sciatic nerve ligation)71 and peripheral mGluR5 agonists can produce thermal 
hyperalgesia72. Trials on mGluR5 antagonists mostly show an effect on thermal sensitivity 
in neuropathic pain models but not on mechanical allodynia71;73. Some groups show an 
effect on spinal nerve ligation model or chronic constriction injury in rats74, but the 
magnitude of effect on mechanical allodynia is below 40% of recovery toward baseline 
values for systemic administration. Dogrul et al showed a 66% reduction in mechanical 
allodynia with a shallow dose-response curve following spinal nerve ligation after 
intrathecal delivery of mGluR5 antagonist75. Fisher et al could show a preventive effect 
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when an antagonist of mGluR5 was administered over 8 days after constriction injury of 
the sciatic nerve but no effect was seen on established mechanical allodynia76;77. 
Altogether, the effects of mGluR5 antagonists are indeed not as potent as the complete 
reversal of established mechanical allodynia through rufinamide. Therefore, we suggest 
mGluR5 is not the major target for rufinamide.  
Therapeutic plasmatic concentration for epilepsy (20-200mol/l)13 and plasmatic 
concentration in our study at the time of anti-allodynic effect (range 68-86mol/l) are in 
the range of concentration used for in vitro testing (100 mol/l). The interest of 
rufinamide at the concentration we used is that the current is not completely blocked but 
globally the channel is less excitable. Nav1.7 is well expressed in basal condition but 
Nav1.7 transcripts or TTX-S currents are not upregulated after SNI or other peripheral 
nerve injuries3. After nerve injury hyperexcitability and ectopic discharges at the 
neuroma or in the dorsal root ganglion4 might be affected by the modulation of Na 
channel properties by rufinamide whereas there is no effect on nociception on a naïve 
nerve. We therefore suggest the anti-allodynic effect of rufinamide is related to its Na 
channel blocking properties. 
 
Limitations of the study 
Differential effect of Rufinamide, amitriptyline and mexiletine on Nav1.7 sodium channel 
We used the ED50 of amitriptyline and mexiletine, 10 M and 100 M respectively. The 
plasma concentrations of these 2 drugs are typically around 0.3 mol/l78  and 2.3-9.3 
mol/l58. Rufinamide was used at 100 mol/l, due to its low solubility in patch clamp 
solution. Our study is not intended to compare the effect size of the drugs on the 
different biophysical properties. The low solubility of rufinamide impeded a comparison of 
the 3 drugs at their ED50 values. The effect on peak current on Nav1.7 as well as on 
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dorsal root ganglion neurons is low but nonetheless statistically significant and 
reproducible. 
 
Effect of DMSO as control 
DMSO was used to dissolve rufinamide despite the potential neurotoxicity with prolonged 
administration at high dose79. It was also used as a treatment option in osteoarthritis80 
but only with relative efficacy on pain scores. We did not see any effect of DMSO on 
naïve animal sensitivity behavior regarding toxicity and compared the anti-allodynic of 
rufinamide to DMSO. 
  
Conclusion and future directions 
We here show that rufinamide dose-dependently alleviates neuropathic pain behavior in 
the SNI model in mice. We show in vitro electrophysiological data that rufinamide 
induces a hyperpolarizing shift in the steady-state inactivation curve, a use dependent–
block and a delay in recovery from inactivation from Nav1.7-mediated current and ex-
vivo data that the same stabilizing effect on inactivation is also present in dorsal root 
ganglion neurons. Sodium channels blockers still belong to the potential targets to treat 
neuropathic pain but often do not come on the market for toxicity or side effects issues. 
Rufinamide is currently on the market and could therefore be used in clinical studies in 
the pain field rapidly. With the low rate of success from current chronic pain therapy, a 
new drug would be highly valued. 
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 Figure Legends 
Fig. 1: Rufinamide (RUF) and amitriptyline (AMI) alleviate mechanical allodynia after SNI 
 A) RUF dose-dependently alleviates neuropathic behavior following SNI from 20 to 240 
min after injection with a peak at 60 min and a loss of effect at 24h, B) AMI alleviates 
neuropathic behavior following SNI from 60 to 240 min after injection and losts its effect 
at 24h, (*p<0.05, **p<0.01, ***p<0.001 vs PreInj). BL=baseline, Preinj=pre-injection 
(1 week after SNI for RUF, 2 weeks for AMI), SNI=spared nerve injury, 
DMSO=dimethylsulfoxide. Values are presented as mean±SD. 
 
Fig. 2: Rufinamide (RUF) and amitriptyline (AMI) differentially affect basal sensitivity and 
activity of naïve animals. A) RUF at 50 mg/kg does not affect withdrawal threshold to 
mechanical stimulation with von Frey filaments as compared to AMI which significantly 
increased the threshold at the dose of 20 mg/kg (not statistically significant for 
10mg/kg), n=8. B) RUF at 50 mg/kg does not affect withdrawal latency to heat 
stimulation as compared to AMI which significantly increased the latency at the dose of 
10 and 20 mg/kg, n=8. C) The total activity (in hours) of the animals was measured 
using the Activ-meter system over a 4 hours period following drug injection and 
compared to activity following saline. AMI (10mg/kg) but not RUF (50mg/kg) significantly 
reduces the activity compared to control, n=6. Data are expressed as median (horizontal 
line) and box and whiskers with first and third quartiles (box), and minimum and 
maximum (whiskers), ns=non-significant, *p<0.05, **p<0.01 versus control (CTRL). 
 
Fig. 3: Drugs inhibit voltage-gated sodium channel Nav 1.7 peak current. A) Percentage 
reduction of peak current after single pulse stimulation B) Example of traces with the 
drug concentrations used afterwards in the biophysical properties testing, respectively 
Figure Legends
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100, 10 and 100 mol/l for rufinamide (RUF), amitriptyline (AMI) and mexiletine (MEX). 
Transients were blanked. 
 
Fig. 4: Drugs induce a shift of inactivation properties of voltage-gated sodium channel 
Nav1.7. Rufinamide (RUF), amitriptyline (AMI) and mexiletine (MEX) (at respectively 
100, 10 and 100 mol/l) induce a hyperpolarizing shift in steady state inactivation (SSI) 
without changing activation (ACT) properties of the voltage-gated sodium channel 
Nav1.7. V1/2 of activation/inactivation, slopes, p values and n values are summarized in 
the tables. Insert: stimulation protocols. CTRL=control, values are mean±SD. 
 
Fig. 5: Drugs induce a prolongation of recovery from inactivation of voltage-gated sodium 
channel Nav1.7. Rufinamide (RUF), amitriptyline (AMI) and mexiletine (MEX), at 
respectively 100, 10 and 100 mol/l, prolonged in a statistically significant way the half 
time (t1/2) of recovery from inactivation of Nav1.7 channel. Values of interest are 
summarized in the table. Insert: stimulation protocol. CTRL=control, values are 
mean±SD. 
 
Fig. 6: Drugs induce a use-dependent block of voltage-gated sodium channel Nav1.7 
Rufinamide (RUF), amitriptyline (AMI) and mexiletine (MEX), at respectively 100, 10 and 
100 mol/l, all induced a statistically significant use-dependent block with stimulation 
frequencies from 2 to 50 Hz (except RUF at 2 Hz). All frequencies are shown in tables but 
for clarity purposes only 10 and 25 Hz are shown graphically. CTRL=control, values are 
mean±SD. 
 
Fig. 7: Effects of rufinamide on freshly dissociated dorsal root ganglion neurons 
3 
 
A) Rufinamide (RUF) at 100 mol/l induced a 10% reduction in sodium peak current 
density (p=0.0084, n=7, horizontal bars represent mean values). B) It significantly 
shifted the steady-state inactivation (SSI) curve to a hyperpolarizing direction (V1/2 of 
inactivation from -64.4±16.8 to -69.35±17.1mV, p<0.0001, n=6) without changing 
activation properties (V1/2 of activation from -40.6±8.4 to -43.4±5.1mV, p=0.17, n=7). 
C) RUF also prolonged recovery from inactivation with half-time (t1/2) for CTRL and RUF 
of respectively 2.58±2.12 and 6.24±5.04ms, p=0.0028, n=6. CTRL=control, values are 
mean±SD. 
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